S. 2252 · 116th Congress
Empowering States to Address Drug Costs Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
Van HollenSponsor1 cosponsor · 1 D
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill expands the purposes for which states may use certain drug pricing information that is disclosed to them by manufacturers through the Medicaid Drug Rebate Program. Specifically, the bill allows states to use such information in furtherance of prescription drug affordability boards or state multi-payer purchasing pools.
What it does: CRS summary · Introduced in Senate · Jul 24, 2019
Empowering States to Address Drug Costs Act
This bill expands the purposes for which states may use certain drug pricing information that is disclosed to them by manufacturers through the Medicaid Drug Rebate Program. Specifically, the bill allows states to use such information in furtherance of prescription drug affordability boards or state multi-payer purchasing pools.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Empowering States to Address Drug Costs Act
Latest action (Jul 24, 2019): Read twice and referred to the Committee on Finance.
Policy area: Health · Origin: Senate · Introduced: Jul 24, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.